LEXINGTON, Mass., June 09, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and ...

Keros’ lead product candidate, KER-065, is being developed for the treatment of neuromuscular diseases, with an initial focus on Duchenne muscular dystrophy.

Keros Therapeutics, Inc. has completed its review of strategic alternatives aimed at maximizing stockholder value and has decided to return $375 million of excess capital to its investors.

Analyst cuts Keros rating to Neutral, citing limited near-term catalysts and cautious investor sentiment. $375M capital return announced, but unclear structure and delayed KER-065 updates weigh on ...

Bank of America Securities analyst Jason Zemansky downgraded Keros Therapeutics, Inc. (NASDAQ:KROS) from Buy to Neutral, lowering the price forecast from $32 to $18. Zemansky noted that Keros has ...

Keros plans to reveal the outcome of its strategic review shortly after the Annual Meeting. 3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads.

Keros’ decision to hand $375 million to shareholders won't be enough to appease investor demands to slash further costs just weeks after layoffs.

Keros Therapeutics is known for its focus on developing protein therapeutics that could offer significant and potentially disease-modifying benefits to patients. Its lead product candidate, KER-065, ...

Product tanker owners are again facing a threat from larger crude carriers cleaning up to load refined cargoes. The latest ...